A number of compounds such as 2,4-dinitrophenol,' salicylate, tetrachlorothyronine, and diphenylhydantoin have been shown to lower the protein-bound iodine level of the blood (1-5). In the case of DNP and salicylate, it was concluded that they acted in part via an inhibition of the pitutary TSH mechanism and partly by an accelerated loss of T4 from the circulation (2, 6). A likely site of action was, therefore, expected to involve binding of T4 to serum proteins.
Diseases, National Institutes of Health, Bethesda, Md.) ( Submitted for publication February 6, 1961 ; accepted April 6, 1961) A number of compounds such as 2,4-dinitrophenol,' salicylate, tetrachlorothyronine, and diphenylhydantoin have been shown to lower the protein-bound iodine level of the blood (1) (2) (3) (4) (5) . In the case of DNP and salicylate, it was concluded that they acted in part via an inhibition of the pitutary TSH mechanism and partly by an accelerated loss of T4 from the circulation (2, 6) . A likely site of action was, therefore, expected to involve binding of T4 to serum proteins.
The ability of various analogs of thyroxine to bind to proteins of serum has been extensively studied with electrophoretic techniques. At least three serum proteins and perhaps four have been described which bind thyroxine (7) . Less direct methods of studying this binding of the thyroid hormones consist of measurement of the "uptake" of triiodothyronine by erythrocytes (8) and the rate of dialysis of T4 through a cellophane membrane (9) . By these techniques several compounds have been found that appear to alter the binding of T4 to serum proteins when studied by these techniques but if whole serum is used, the effect cannot be localized to specific proteins. Thus it has been suggested from dialysis studies that salicylates and DNP act by inhibiting T4 binding to serum proteins. Electrophoretic studies in barbital buffer of sera containing salicylate failed to show any influence on the distribution of T4 between TBG and albumin, nor was there any change in the T4 binding capacity measured under these conditions (2) . Since then it has been shown that barbital buffer inhibits T4 binding to prealbumin (10) and Ingbar has stated that alpha zone in paper electrophoresis; TBPA = thyroxinebinding prealbumin; TCT=DL-tetrachlorothyronine; TSH =thyroid-stimulating hormone.
salicylate could interfere with T4 binding in electrophoretic systems in buffers other than barbital (11) . It was therefore desired to examine T4 binding in the presence of these four agents in a system where prealbumin binding of T4 could be observed. Furthermore, the possible correlation between the effect of inhibition of thyroxine binding to TBPA and to TBG by various drugs with the in vivo effect of these drugs on the PBI was studied.
METHODS
A single batch of pooled normal human serum obtained from the Baxter Laboratories was used in all the studies. Butanol solutions of thyroxine were evaporated to dryness in vacuo prior to the addition of serum. The mixtures were incubated at 4°C for at least 24 hours before use and were kept in the cold until used.
Electrophoresis in 0.12 M ammonium carbonate buffer, pH 8.4, was performed at room temperature on 3.75 X 49 cm strips of Whatman no. 3 MM filter paper. The edges of the strips were coated with a thin border of paraffin. The strips were saturated with buffer and suspended horizontally between two plastic clamps in a closed system. The strips were equilibrated for at least 1 hour before the serum was applied. The anodal chamber received an excess of buffer solution just before the current was turned on. Thirty ,ul of serum was added approximately 8 cm from the anode just before the voltage was applied. In nearly all cases the reverse flow technique was employed (12) with a constant voltage of 80 v.
Two types of studies were carried out. In the first, the inhibitor was added to the serum which was then run in reverse flow electrophoresis. In the second, we followed the suggestion of Ingbar (11) Table I have been corrected for the endogenous T4 of the serum used. Labeled thyroxine was obtained from Abbott Laboratories and chromatographed before use; when necessary it was purified until better than 90 per cent pure (12) . DNP and sodium salicylate were reagent grade and TCT was a generous gift of Dr. Jacob Lerman. When drugs were added directly to the ammonium carbonate buffer, the pH was adjusted after addition of the drug.
Male guinea pigs of the NIH strain were used. In experiment III (Table II) thyroidectomy was checked by thorough examination of the tracheal region, and all animals suspected of incomplete thyroidectomy were discarded. They were then divided into three groups: an uninj ected control group, a thyroxine-inj ected control group, and a group receiving both thyroxine and TCT. The thyroxine treatment was started 8 days after thyroidectomy and was continued for 12 days. During the last 5 days the third group of guinea pigs received, in addition, subcutaneous injections of TCT. All animals were exsanguinated 3 to 4 hours after the last injection.
RESULTS
Initial experiments, in which salicylate or DNP was added to the serum before electrophoresis, showed that both these agents tended to displace T4 from TBPA onto TBG. However, experiments in which these agents were added to the buffer gave more reproducible results, and most of the studies presented here will deal with the latter technique. Figures 1C and 2C) . At 2.7 x 10-7 M T4 ( Figure 3C ) there was practically no radioactivity left in the prealbumin area. At these low T4 concentrations most of the T4 displaced from TBPA was bound by TBG. In the presence of higher amounts of T4, the TBG became saturated and the displaced T4 was bound to albumin (see Table I ). That there was no displacement from albumin was ascertained in studies with standard paper electrophoresis in which albumin is permitted to migrate from the origin. Thyroxine stayed with the albumin and no radioactivity was found at the origin. Displacement of T4 from prealbumin as a function of DNP or salicylate concentration is also demonstrated in Table I . Displacement by salicylate could still be demonstrated at 3 X 10 4 1\1, a level easily attained during salicylate therapy (4.1 mg per 100 ml), and was marked at 1 to 3 x 10-3 M levels which have been shown to be accompanied by lowering of the PBI (2) .
TCT also could displace T4 from serum proteins, in this case from TBG ( Figures 3A and 3B ). Some displacement of T4 from TBG can be observed at TCT levels as low as 10-7 M. The displacement can also be demonstrated when the compound is added directly to serum. Comparison of Figures 3B and 3C reveals the striking difference between TCT and salicylate in the electrophoretic distribution of T4. In contrast to salicylate and DNP, T4 displacement is from TBG. At low levels of TCT, the T4 that is not bound to TBG is found to be associated with TBPA. At very high levels of TCT there is also inhibition of binding of T4 to TBPA, and the thyroxine thus displaced appears on albumin (Table I) .
In view of the potent T4 displacing action of TCT, it was important to establish that this com- Table I ), and at drug concentrations that obtain clinically (15) imply a difference at the prealbumin binding site, tion of thyroxine are functions of the concentraalthough higher concentrations of the drug might tion of unbound thyroxine (7). Any factor which have shown displacement here also. In any case, decreases protein binding of T4 will, if the total the present finding, that diphenylhydantoin com-concentration of thyroxine is unchanged, increase petes with thyroxine for sites on TBG is a reas-the concentration of free thyroxine. Consequently, onable explanation for the depression of PBI. It an important factor in the control of the PBI is is surprising, however, that a compound so unlike the serum concentration of available binding sites the iodothyronines can compete for what appears for the T4. Given a constant output of T4 from to be a highly specific binding site on TBG. the thyroid, loss of these sites by competition with a variety of drugs leads inevitably to a depression DISCUSSION in the PBI level. This cause for the reduction There is available a body of evidence which sug-of the PBI concentration in the circulation must be gests that both the effect and the rate of degrada-clearly differentiated from that resulting from a decrease or absence in the thyroxine-binding proteins, as in the case of nephrosis (16) , congenital absence of a binding protein (17) , or after treatment with methyl testosterone (18) . Presumably the homeostatic mechanisms operating to reduce the PBI are similar in all these circumstances. Inhibition of thyroxine binding to prealbumin has been clearly shown with both salicylate and dinitrophenol. Since there is no evidence that, in the concentrations used, either drug denatures serum proteins, and since there is a good correlation between concentration of drug and degree of inhibition of thyroxine binding, it may be assumed that these drugs compete with thyroxine for binding sites on TBPA. It would appear from the quantities of drug required that the association constant of both of these drugs for TBPA is several orders of magnitude lower than that of thyroxine. Neither of these drugs affects T4 binding to TBG.
It is probable that addition of the drug to the buffer is the better method. If the association constant of drug for TBPA is not high it seems quite likely that if drug is added only to serum, there will be, during electrophoresis, a continual removal of unbound drug. If drug is added to the buffer, a reservoir is provided so that the concentration of drug in the buffer will approach the concentration of free drug. As a result of the uncertainty in the concentration of drug bound to protein, it is not possible to calculate accurately a ratio of binding constants of drug/T4 for TBPA. Doubt has recently been expressed regarding the physiological importance of TBPA as a binding protein for T4 at pH 7.6 (19) . The present data with salicylate and DNP are nevertheless compatible with a significant role for TBPA.
The results with TCT are more easily interpreted because of the apparent high affinity constant of this compound for TBG; although bound less strongly, its binding affinity for TBG probably differs from that of T4 by less than an order of magnitude. Since equilibrium is not attained in electrophoresis, a more exact statement of the relative affinities is not possible. At high concentrations TCT also inhibits T4 binding to TBPA. Diphenylhydantoin appears not to have this second action. None of the compounds tested appeared to inhibit T4 binding to albumin. This may be a quantitative phenomenon, since albumin is present in serum at a concentration of -5 X 10-4 M [with four sites for T4 (20) ] and extremely high concentration of the drugs would be required. Furthermore, it is unlikely that T4 binding to albumin normally plays a significant role in thyroxine metabolism, since the PBI of analbuminemic patients is normal (21) . It is highly probable that other drugs will be found that can alter the PBI by this mechanism. It would behoove investigators studying thyroid function during therapy with presumably unrelated drugs to take cognizance of this fact.
It may be concluded, therefore, that a decrease in the number of available binding sites either in TBG or in prealbumin, produced by TCT and diphenylhydantoin or by DNP and salicylate, will (by mass law relations) increase the free T4 at the expense of the fraction bound. This will in turn accelerate T4 disappearance from the circulation and ultimately lower the PBI to a new steady state value at which the free T4 concentration may be perfectly normal. The in vivo experiments with TCT, which produced a consistent fall in the PBI both in normal guinea pigs and in thyroidectomized, thyroxine-treated animals, offer only indirect support for this hypothesis, since no electrophoretic results on guinea pig sera are reported. Studies of guinea pig sera by the above techniques showed T4 binding only in the albumin area, and T4 displacement from one protein to another within this area would not be detectable.
The above considerations may also be applicable in certain short-term assays of thyromimetic (and antithyroxine) materials. Are such effects, as for example, goiter prevention, due to inherent thyroxine-like activity or do they merely represent an elevation of free T4 as a result of thyroxine displacement from one of the serum proteins?
Can decreased T4 binding explain the other phenomena produced by DNP and salicylate? Of the diverse effects of salicylate on thyroid function, loss of binding sites can probably explain the accelerated disappearance of radioactive T4 from the circulation (2, 22, 23) . Whether or not the other effects can be similarly explained is not certain at present. The whole problem must be reconsidered from the point of view of intracellular binding proteins and the effect of the drugs upon these.
